Background
In the United States, type 2 diabetes mellitus affects nearly 30.3 million people, or 9.4% of the population [
1]. Type 2 diabetes is a complex, age-associated metabolic disorder characterized by low-grade chronic inflammation [
2], hyperinsulinemia [
3], insulin resistance, and β-cell dysfunction. It also increases the risk for numerous vascular-related comorbidities, including end-stage renal [
4], cardiovascular [
5], cerebrovascular [
6], coronary artery [
7], peripheral vascular [
8], chronic kidney [
9], and ophthalmological diseases [
10]. The epidemic is reflected in the increase of diabetic individuals with cardiovascular disease (CVD) within the last several decades [
11]. CVD is the leading cause of death and takes up the highest proportion of healthcare costs for individuals with diabetes [
12,
13]. In addition to the aged population, diabetes also causes disproportionate morbidity and mortality among minority groups in the U.S., including African Americans, Hispanics, and Native Americans [
1]. In order to create diagnostic tools and therapies that will benefit a broad spectrum of the population, more knowledge of the mechanisms that drive vascular disease in diabetes is needed.
Many of the cardiovascular diseases associated with diabetes mellitus can be attributed to endothelial dysfunction, which is known to cause atherosclerosis [
14,
15]. In diabetes mellitus, endothelial dysfunction occurs when blood vessels do not properly vasodilate due to an imbalance in endothelium-derived factors [
16]. Oxidative stress and inflammation contribute to the vascular dysfunction [
16]. Furthermore, endothelial dysfunction has been associated with insulin resistance [
17] and impaired β-cell function [
18]. Yet, finding a way to target inflammation to improve vascular endothelial health remains a challenge in clinical trials [
19].
Recent data indicate that extracellular vesicles (EVs), which are membrane-derived particles, facilitate intercellular communication in various disease processes [
20,
21]. Ranging in size from ~ 30 to 400 nm, EVs shuttle molecular cargo, including lipids, nucleic acids, and proteins, in a cell-to-cell manner. Based on their mode of biogenesis, EVs can be categorized as (a) exosomes, which are secreted from multivesicular bodies upon fusion with the plasma membrane, (b) microvesicles, which pinch off the extracellular surface of the plasma membrane, and (c) apoptotic bodies, which are shed from the plasma membrane during apoptosis of a cell [
22]. More recently, fractions isolated during differential ultracentrifugation have been referred to as small EVs (sEVs) and medium-sized EVs, rather than, respectively, exosomes and microvesicles [
23].
EVs isolated from blood samples can potentially lead to new and improved diagnostic tools and therapies [
24] for a variety of diseases, including diabetes mellitus [
25]. For the past few decades, significant attention has been focused on the role of larger EVs, called microparticles, in type 2 diabetes. A recent meta-analysis of 34 studies showed that when compared to non-diabetic controls, individuals with type 2 diabetes have higher levels of total circulating microparticles as well as microparticles derived from platelets, monocytes and endothelial cells [
26]. Recent technological advancements have allowed for analysis of EVs (~ 30–400 nm) smaller than microparticles. According to previous longitudinal and cross-sectional studies from our group, diabetic individuals have higher circulating levels of EVs in their plasma than euglycemic controls [
27]. Furthermore, we found that insulin resistance increased EV secretion and that EVs from diabetic individuals increased cytokine secretion in monocytes. These findings agree with other human studies suggesting an important role of EVs in facilitating insulin resistance and inflammation [
28,
29].
Through the delivery of molecular cargo, EVs can elicit functional effects on target cells, including pathological effects [
30]. Not as extensively explored in diabetes research is the possibility that EVs contribute to endothelial dysfunction and thereby lead to the progression of cardiovascular disease. The idea was examined by a recent study, which found that endothelial dysfunction in non-diabetic mice can be induced by treatment with serum-derived EVs containing arginase 1 from diabetic mice [
31].
To study the molecular cargo that may contribute to inflammation, insulin resistance and endothelial dysfunction in diabetes mellitus, here we profiled the inflammatory protein content of EVs in a longitudinal cohort of diabetic and euglycemic humans. We then further explored our data by testing the effects of EVs from diabetic individuals on the actin cytoskeletal structure and migratory behavior of human aortic endothelial cells.
Discussion
Our previous work on a human cohort showed that diabetic individuals have increased levels of plasma EVs and suggested that EVs may be involved in the inflammatory pathways of diabetes mellitus [
27]. In this study, we examined the inflammatory cargo of EVs from diabetic individuals. Through analyses of our longitudinal cohort, we found significant associations between EV inflammatory protein levels and diabetes status. Furthermore, we found that EVs from diabetic individuals altered the migration and morphology of human aortic endothelial cells when compared to euglycemic controls.
Inflammation is a contributor to endothelial dysfunction [
16], which leads to the development of vascular complications in diabetes. Hence, we attempted to elucidate the role of EVs in the progression of these comorbidities by studying EV-associated factors that are involved in inflammation. Previous research on EVs in diabetic inflammation have examined EVs from adipose tissue and characterized microRNA content within these vesicles [
25,
51]. Our work in this study focused on EVs derived from the circulation of diabetic individuals and profiling the EV protein content by testing a large panel of inflammatory biomarkers.
Notably, EV VEGF-A levels were associated with diabetes status, HOMA-B and HOMA-IR levels in the longitudinal cohort, as well as in our cross-sectional analysis of diabetes status and HOMA-IR levels at time 2. Our results corroborate with a previous cross-sectional study that observed higher levels of VEGF in platelet-poor plasma EVs from diabetic individuals [
52]. Our longitudinal study expands upon those findings by suggesting that individuals who develop diabetes over time will acquire higher levels of VEGF-A in their circulating EVs.
Here, we report that EVs from diabetic individuals increased the migration of endothelial cells when compared to EVs from euglycemic individuals. Given the link between cell migration and VEGF content, our findings would be consistent with studies also examining EVs and cell migration but looking at the effects of EV VEGF-A levels on angiogenesis in cancer. Numerous studies have shown that the isolation of EVs-containing VEGF from cancer cells promotes endothelial cell migration and angiogenesis in vitro [
53‐
57]. These studies point to VEGF in EVs as a potent inducer of tumor angiogenesis.
VEGF-A content in EVs is important due to the strong connection between VEGF-A levels and the potential severity of an individual’s diabetes. In a clinical study of euglycemic and diabetic individuals, researchers showed that levels of hemoglobin A1c (HbA1c) were positively correlated with plasma VEGF levels [
58]. In agreement with that finding, another study found that concentrations of VEGF-A and receptors 1 and 2 levels were similar in serum samples from patients with well-controlled diabetes and healthy individuals [
59]. This result is significant as the individuals with well-controlled diabetes displayed no signs of vascular-related complications. Hence, quantifying VEGF-A in EVs may be a valuable tool in measuring the progression of diabetes. Our cohort study offers such information, in addition to data on a variety of other inflammatory biomarkers.
However, it is also important to note the complex relationship between VEGF levels and the progression of diabetes mellitus. Plasma VEGF levels may not always reflect intracellular organ levels of VEGF [
60]. Furthermore, employing anti-VEGF interventions in response to increased VEGF levels may interfere with essential processes throughout the body, including wound healing and collateral vessel development [
60]. Hence, before EVs can be deemed as a robust biomarker and therapeutic target for diabetes, it would be necessary to further explore the role of EVs in shuttling VEGF.
Our data indicate that EVs from individuals with diabetes contain cargo that affect cell morphology and migration. In the Transwell Boyden assays, we observed that medium-sized EVs (10K fraction) from diabetic individuals enhanced cell migration when compared to cells incubated with EVs from euglycemic individuals. Hence, our finding suggests that EVs from diabetic individuals carry greater chemoattractant than EVs from euglycemic individuals. The implication of our findings agrees with another report showing higher levels of VEGF in medium-sized EVs from individuals with diabetes, in which the EVs were isolated from the 10K spin of differential ultracentrifugation [
52]. Given that VEGF-A levels are more abundant in the EVs of diabetic individuals, we expected the chemoattractant of those EVs to induce proangiogenic behavior in target cells. The hypothesis is in line with immunofluorescence experiments showing that endothelial cells incubated with medium-sized EVs (10K fraction) in diabetes displayed more actin-rich, membrane protrusions and ruffles than compared to cells incubated with EVs from the euglycemic control. Lamellipodia are known to enhance cell migration through actin polymerization and reorganization, which drive the protrusions of the leading edges of cells [
50]. Hence, our results suggest that EVs from diabetic individuals carry cargo that promote endothelial cell migration, and thereby, angiogenesis.
The results from the proteomic and in vitro studies are consistent with the excessive angiogenesis that occurs in certain diabetic comorbidities, including diabetic retinopathy [
61]. Conversely, our findings may also reflect a compensatory mechanism for comorbidities involving deficient angiogenesis and endothelial dysfunction, including heart disease and stroke [
61]. The role of angiogenic factors in vascular disease and diabetes is multi-dimensional and requires further research, as current attempts at angiogenic therapies have drawbacks, including the inability to make targeted deliveries [
62]. Those issues could potentially be addressed by engineering EVs to serve as novel carriers of angiogenic and anti-angiogenic factors to selected organs in the body.
In addition to VEGF-A, we found multiple EV inflammatory proteins that may give further insight on the pathophysiology of diabetes, including cluster of differentiation 40 (CD40). The interaction between CD40 and its corresponding ligand, CD40L, is known to induce platelet activation, thereby leading to inflammation and atherosclerosis [
63]. In a study of humans who had no history of vascular complications, when compared to controls, individuals with type 2 diabetes had higher levels of soluble CD40L, which have been associated with an increased risk for cardiovascular events [
64]. In our longitudinal study, EV levels of CD40 are significantly associated with the status of individuals who transitioned from a euglycemic to diabetic diagnosis. Thus, CD40 content in EVs may help to predict vascular disease for diabetes mellitus.
Hepatocyte growth factor (HGF) is another EV-associated inflammatory protein that may be relevant to vascular disease. Levels of HGF in EVs are significantly associated with HOMA-IR levels in our longitudinal analysis of the cohort and in our cross-sectional analysis of time 2. It has been reported that HGF may have protective effects against insulin resistance by allowing for regeneration of β cells in diabetes mellitus [
65]. Furthermore, HGF has been found to modulate anti-inflammatory responses in murine models [
65]. Hence, examining EV HGF content may provide more knowledge on the biological mechanisms that counteract insulin resistance and elucidate the complex role EVs play in individuals with diabetes.
Similar to HGF, EV levels of IL-18R1, a receptor for IL-18, was found to be significantly associated with HOMA-IR in our longitudinal analysis and in our cross-sectional analysis of time 2. It has been found that plasma IL-18 levels are significantly associated with HOMA-IR, and this relationship is independent of obesity and diabetes status [
66]. In turn, EVs may serve as a useful assessment of insulin resistance in diabetes mellitus.
Here, we have analyzed levels of EV inflammatory proteins. Many cytokines can be encapsulated in EVs and have been shown to be biologically active [
67]. Intriguingly, cytokines in the soluble versus EV-encapsulated fraction differ and may depend on the biological system and stimulus [
67]. It would be interesting in the future to examine the inflammatory profiles of the soluble along with EV-associated fraction. This avenue of exploration would build upon previous literature showing that microRNA profiles in the EV-enriched serum fraction differed between individuals with normal glucose tolerance and diabetes, but the microRNAs did not differ in the soluble fraction of serum [
68]. Therefore, biological cargo may be sorted differentially into the soluble versus EV-associated fractions in type 2 diabetes mellitus.
Lastly, results from our functional assays show that the 10K fraction, containing medium-sized EVs, caused alterations in recipient endothelial cells. It has only recently been appreciated that EVs from the 10K and 100K fractions may carry different molecular cargo and, hence, may elicit different biological functions [
23]. In general, most studies have focused on one fraction of EVs when examining effects on endothelial cells. In fact, many previous studies omitted the 10K step of differential ultracentrifugation and thus collected both medium-sized and sEVs [
56,
69,
70]. sEVs obtained from the 100K fraction have been demonstrated to elicit effects on endothelial cell function [
55,
57,
71,
72,
73]. Other EV isolation techniques, that non-discriminately collect for both small and medium-sized EVs, have also been done for assays studying endothelial cell migration [
53]. Here, our findings contribute to the more limited literature on the role of EVs isolated from the 10 K fraction of differential ultracentrifugation on endothelial cell migration and angiogenesis [
74]. The role of medium-sized EVs in endothelial cell migration may be connected to the described importance of these vesicles in mediating endothelial dysfunction and cardiovascular disease [
75]. We have evidence pointing towards the proangiogenic effects of medium-sized EVs (10 K fraction), which may contribute to vascular complications in diabetes. Hence, these results may further our understanding of the properties and functions that differentiate medium-sized EVs from other types of EVs within the context of pathological conditions.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.